Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long Term, Open Label, Randomised Study in Patients With Type 2 Diabetes, Comparing the Combination of Rosiglitazone and Either Metformin or Sulfonylurea With Metformin Plus Sulfonylurea on Cardiovascular Endpoints and Glycaemia
Brief Summary: This study is a phase 3b, multicentre, randomised, open label, parallel group study. A 4-week run-in period will be followed by a median of 6 years of treatment with study medication in addition to continuation of background glucose lowering therapy. Patients inadequately controlled on background metformin will be randomised to receive, in addition to metformin, either rosiglitazone or a sulfonylurea(glibenclamide, gliclazide or glimepiride) in a ratio of 1:1. Patients inadequately controlled on background SU will be randomised to receive, in addition to SU, either rosiglitazone or metformin in a ratio of 1:1. Equal numbers of patients receiving background metformin and SU at entry will be entered into the study.


Options:
A: Intervention Type: DRUG; Name: muraglitazar; Assigned to Arm(s): N/A
B: Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 100 mg, Drug: Antihyperglycemic agent(s) | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 300 mg, Drug: Antihyperglycemic agent(s) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Antihyperglycemic agent(s), Drug: Placebo | Intervention Type: DRUG; Name: Canagliflozin 100 mg; Assigned to Arm(s): Canagliflozin 100 mg | Intervention Type: DRUG; Name: Canagliflozin 300 mg; Assigned to Arm(s): Canagliflozin 300 mg | Intervention Type: DRUG; Name: Antihyperglycemic agent(s); Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: BI 1356 5mg, once daily; Type: EXPERIMENTAL; Interventions: Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, Drug: BI 1356 | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo identical to BI 1356 5mg, Drug: Glimepiride | Intervention Type: DRUG; Name: Placebo identical to BI 1356 5mg; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride
D: Arm Label: rosiglitazone in addition to background metformin; Type: EXPERIMENTAL; Interventions: Drug: Rosiglitazone, Drug: Metformin | Arm Label: rosiglitazone in addition to background sulfonylurea; Type: EXPERIMENTAL; Interventions: Drug: Rosiglitazone, Drug: Sulfonylurea | Arm Label: Sulfonylurea in addition to background metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfonylurea, Drug: Metformin | Arm Label: Metformin in addition to background sulfonylurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfonylurea, Drug: Metformin | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): rosiglitazone in addition to background metformin, rosiglitazone in addition to background sulfonylurea | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): Metformin in addition to background sulfonylurea, Sulfonylurea in addition to background metformin, rosiglitazone in addition to background sulfonylurea | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin in addition to background sulfonylurea, Sulfonylurea in addition to background metformin, rosiglitazone in addition to background metformin

Answer: D